Skip to main content
SpringerLink
Log in

Tumoren nach Nierentransplantation

  • Chapter
  • First Online:
Weiterbildung Onkologie

  • 1625 Accesses

Zusammenfassung

Nierentransplantierte Patienten haben im Vergleich zur Gesamtbevölkerung ein 2- bis 4-fach erhöhtes Tumorrisiko, wobei das Risiko besonders für Hauttumoren, Lymphome und Nierenzellkarzinome erhöht ist. Ursächlich für die erhöhte Tumorinzidenz ist die durch die immunsuppressive Therapie bedingte eingeschränkte überwachungskapazität des Immunsystems in Bezug auf maligne Veränderungen sowie die erhöhte Anfälligkeit für sogenannte Onkoviren. Hervorzuheben ist hier die Bedeutung der EBV-Primärinfektion bei der Entstehung von Posttransplantationslymphomen. Allerdings ist auch eine chronische Nierenerkrankung selbst mit einem erhöhten Risiko, insbesondere für Nieren- und Blasentumoren, vergesellschaftet. Bezüglich der Art der immunsuppressiven Medikation bestehen Unterschiede für das Tumorrisiko. Das gehäufte Auftreten bestimmter Tumoren und ihre Risikofaktoren haben Implikationen für die Prävention, Früherkennung und Behandlung von Tumoren nach Nierentransplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 17.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Engels EA, Pfeiffer RM, Fraumeni JF et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17):1891–1901

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Grulich AE, Leeuwen MT van, Falster MO et al (2007) Incidence of cancers in people with HIV/Aids compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67

    Article  PubMed  Google Scholar 

  3. Vajdic CM, McDonald SP, McCredie MR et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823–2831

    Article  PubMed  CAS  Google Scholar 

  4. Adams Pl (2006) Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 47(4 Suppl 2):65–85

    Article  Google Scholar 

  5. Kauffman HM, Cherikh WS, Mcbride MA et al (2006) Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 19(8):607–620

    Article  PubMed  Google Scholar 

  6. Sheil AG, Disney AP, Mathew TH et al (1993) De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25:1383–1384

    PubMed  CAS  Google Scholar 

  7. Bordea C, Wojnarowska F, Millard PR et al (2004) Skin cancers in renal transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 77:574–579

    Article  PubMed  CAS  Google Scholar 

  8. Penn I (1998) Occurrence of cancers in immunosuppressed organ transplant recipient. Clin Transpl 12:147–158

    Google Scholar 

  9. Evens AM, Roy R, Sterrenberg D et al (2010) Post-transplantation lymphoproliferative disorders: diagnosis, prognosis and current approaches to therapy. Curr Oncol Rep 12:383–394

    Article  PubMed  Google Scholar 

  10. Klatte T, Seitz C, Waldert M et al (2010) Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. BJU Int 105:1260–1265

    Article  PubMed  Google Scholar 

  11. Webster AC, Craig JC, Simpson JM et al (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7(9):2140–2151

    Article  PubMed  CAS  Google Scholar 

  12. Urwin HR, Jones PW, Harden PN (2009) Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 87(11):1667–1671

    Article  PubMed  Google Scholar 

  13. Opelz G, Daniel V, Naujokat C et al (2009) Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 88:962–967

    Article  PubMed  Google Scholar 

  14. Bonsib SM (2009) Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol 4:1998–2007

    Article  PubMed  Google Scholar 

  15. Hojo M, Morimoto T, Maluccio M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719):530–534

    Article  PubMed  CAS  Google Scholar 

  16. Webster AC, Woodroffe RC, Taylor RS (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: metaanalysis and metaregression of randomized trial data. BMJ 331:810

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Végso G, Sebestyén A, Paku S et al (2007) Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 31:1003–1008

    Article  PubMed  Google Scholar 

  18. Robson R, Cecka JM, Opelz G et al (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5:2954–2960

    Article  PubMed  CAS  Google Scholar 

  19. Sørensen HT, Mellemkjaer L, Nielsen GL et al (2004) Skin cancers and non- Hodgkin lymphoma among users of sytemic glucocorticoids: a population- based cohort study. J Natl Cancer Inst 96(9):709–711

    Article  PubMed  Google Scholar 

  20. Chapman TM, Keating GM (2003) Basiliximab: a review of its use as an induction therapy in renal transplantation. Drugs 63(24):2803–2835

    Article  PubMed  CAS  Google Scholar 

  21. Vincenti F, Charpentier B, Vanrenterghem Y et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10(3):535–546

    Article  PubMed  CAS  Google Scholar 

  22. Guba M, Breitenbuch P von, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135

    Article  PubMed  CAS  Google Scholar 

  23. Kauffman HM, Cherikh WS, Cheng Y et al (2005) Maintenance immunosuppression with target-of-rapamycine inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883–889

    Article  PubMed  CAS  Google Scholar 

  24. Alberu J, Pascoe MD, Campistol JM et al (2011) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24- months results from the CONVERT trial. Transplantation 92:303–310

    Article  PubMed  CAS  Google Scholar 

  25. Ekberg H, Bernasconi C, Tedesco-Silva H et al (2009) Caclineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 9:1876–1885

    Article  PubMed  CAS  Google Scholar 

  26. Opelz G, Daniel V, Naujokat C (2007) Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective trial. Lancet Oncol 8:212–218

    Article  PubMed  CAS  Google Scholar 

  27. Salgo R, Gossmann J, Schöfer H et al (2010) Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 10:1385–1393

    Article  PubMed  CAS  Google Scholar 

  28. Sampaio MS, Shah YW, Bunnapradist S, Hutchinson IV (2012) Association of immunosuppressive maintenance regimens with lymphoproliferative disorder in kidney transplant recipients. Transplantation 93:73–81

    Article  PubMed  CAS  Google Scholar 

  29. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):1–157

    Google Scholar 

  30. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management. J Am Acad Dermatol 65:263–279

    Article  PubMed  Google Scholar 

  31. Bustami RJ, Ojo AO, Wolfe RA et al (2004) Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 4(1):87–93

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrologische Abteilung der Medizinischen Klinik III, Universitätsklinikum Dresden, Dresden, Deutschland

    M. Opgenoorth

  2. Nephrologische Abteilung der Medizinischen Klinik III, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    C. Hugo

Authors
  1. M. Opgenoorth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Hugo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Strahlentherapie und Radio-Onkologie, Ruhr-Universität Bochum, Marienhospital Herne, Herne, Germany

    Irenäus A. Adamietz

  2. Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Frankfurt, Frankfurt, Germany

    Wolf O. Bechstein

  3. Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover, Germany

    Hans Christiansen

  4. Urologikum Lübeck, Lübeck, Germany

    Christian Doehn

  5. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Andreas Hochhaus

  6. TagesTherapieZentrum (TTZ), Universitätsmedizin Mannheim, Mannheim, Germany

    Ralf-Dieter Hofheinz

  7. Klinik für Gynäkologie, Charité - Universitätsmedizin Berlin, Berlin, Germany

    Werner Lichtenegger

  8. Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Germany

    Dirk Schadendorf

  9. Klinik für Gynäkologie und Geburtshilfeum, HELIOS Klinikum Berlin-Buch, Berlin, Germany

    Michael Untch

  10. Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig, Germany

    Christian F. Wittekind

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Opgenoorth, M., Hugo, C. (2015). Tumoren nach Nierentransplantation. In: Adamietz, I., et al. Weiterbildung Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44835-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44835-9_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44834-2

  • Online ISBN: 978-3-662-44835-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation